BioCentury
ARTICLE | Clinical News

Trebananib regulatory update

January 27, 2014 8:00 AM UTC

The European Commission granted Orphan Drug designation to Amgen's trebananib to treat ovarian cancer. The recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins is in Phase III tes...